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Abstract
Background—Cyp1a1-Ren2 transgenic rats [strain name: TGR(Cyp1a1Ren2)], administered
indole-3-carbinol (I3C) develop angiotensin (ANG) II-dependent hypertension due to hepatic
expression of the Ren2 renin gene. Although AT1 receptor blockade prevents the development of
hypertension and normalizes the elevated arterial blood pressure of Cyp1-Ren2 rats, little
information is available regarding the blood pressure and renal functional responses to direct
inhibition of renin in this high circulating renin model of ANG II-dependent hypertension. The
present study was performed to determine the effects of acute direct renin inhibition with aliskiren
on blood pressure and renal hemodynamics in Cyp1a1-Ren2 rats with ANG II-dependent
malignant hypertension.
Methods—Mean arterial pressure (MAP) and renal hemodynamics were measured in
pentobarbital-anesthetized male Cyp1a1-Ren2 rats during control conditions and following
administration of the renin inhibitor, aliskiren (10 mg/kg, iv).
Results—Rats induced with I3C had higher MAP (194±7 vs. 141±2 mmHg, P<0.001), lower
renal plasma flow (RPF; 2.47±0.23 vs. 4.17±0.35 ml/min.g, P<0.001), and lower glomerular
filtration rate (GFR; 1.01±0.07 vs. 1.34±0.06 ml/min.g, P=0.01) than noninduced Cyp1a1-Ren2
rats (n=5). Aliskiren administration decreased MAP (194±7 to 136±2 mmHg, P<0.001) and
increased RPF (2.47±0.23 vs. 4.31±0.20 ml/min.g, P<0.001) in hypertensive but not in
normotensive rats, without altering GFR.
Conclusions—Acute renin inhibition with aliskiren normalizes MAP and RPF in Cyp1a1-Ren2
rats with malignant hypertension. The normalization of MAP and RPF following acute renin
inhibition indicates that renin generated by expression of the Ren2 gene is responsible for the
maintenance of malignant hypertension and the associated reduction in renal hemodynamic
function in Cyp1a1-Ren2 rats.
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Introduction
The transgenic rat line with inducible expression of the mouse Ren2 renin gene [strain name:
TGR (Cyp1a1Ren2)] was created by inserting the mouse Ren2 renin gene, fused to an 11.5
kb fragment of the cytochrome P450 1a1 (Cyp1a1) promoter, into a neutral genomic site on
the Y chromosome of the Fischer 344 rat.1 Cyp1a1, which catalyzes the oxidation of a wide
range of endogenous lipophilic compounds and xenobiotics, is not constitutively expressed,
but is highly inducible upon exposure to various aryl hydrocarbons such as indole-3-carbinol
(I3C).2,3 Induction of Cyp1a1 is mediated by the aryl hydrocarbon receptor, which is a
basic helix-loop-helix-transcription factor that binds to specific DNA elements in the
Cyp1a1 promoter.2 Rats transgenic for the Cyp1a1-Ren2 construct do not constitutively
express the Ren2 renin gene. Rather, the Ren2 gene is expressed, primarily in the liver, only
upon induction of the Cyp1a1 promoter by dietary administration of aryl hydrocarbons such
as I3C.1
Administration of I3C at a dose of 0.3% wt/wt induces the development of ANG II-
dependent malignant hypertension,4–6 which is a form of severe hypertension characterized
by fibrinoid necrosis of arterioles and vascular damage in many tissues, including the
kidney.1,5 In rats, this condition manifests as a rapid rise in systemic blood pressure
accompanied by a significant loss of body weight, polyuria, polydipsia, piloerection,
lethargy, and hunched posturing.1,5,6 In addition, Cyp1a1-Ren2 transgenic rats with
malignant hypertension exhibit increases in plasma renin activity (PRA), plasma ANG II
levels and intrarenal ANG II levels.6 Although AT1 receptor blockage prevents the
development of hypertension and normalizes the elevated arterial blood pressure of
hypertensive Cyp1a1-Ren2 transgenic rats,6,7 little information is available regarding the
blood pressure and renal functional responses to direct inhibition of renin in the high
circulating renin model of ANG II-dependent malignant hypertension.
Recently, the first direct renin inhibitor, aliskiren, was approved for the treatment of
hypertension.8 Aliskiren suppresses the activity of renin to catalyze the conversion of
angiotensinogen (AGT) to ANG I.9 While aliskiren was designed to inhibit human renin
(IC50 = 0.6 nM), it also effectively inhibits the activity of mouse renin (IC50 = 4.5 nM).8
The compound binds the active site of both soluble and receptor-bound renin and prorenin,
thus acting to suppress both plasma renin activity (PRA) and the production of the
vasoactive substance ANG II.8 In human trials, chronic administration of aliskiren results in
significant and sustained suppression of hypertension and PRA.10 Likewise, chronic
administration of aliskiren in TG(mRen2)27 rats that constitutively express the mouse Ren2
renin gene suppresses hypertension, reduces renal and cardiac pathologies associated with
increased blood pressure, and prevents the increases in both kidney and plasma ANG II
levels.11,12 However, little is known about the acute effects of direct renin inhibition on
blood pressure and renal hemodynamics in ANG II-dependent malignant hypertension. The
present study was performed to address the hypothesis that acute direct renin inhibition with
aliskiren normalizes arterial blood pressure and increase renal hemodynamic function in
Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension.
Methods
The experimental procedures in this study conform to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committees of Tulane University Health Sciences Center.
Experiments were performed on adult male transgenic rats [TGR(Cyp1a1Ren2)] with
inducible expression of the mouse Ren2 renin gene1. All transgenic rats used in the present
study were bred at Tulane University School of Medicine from stock animals supplied by
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Harlan UK Limited, Bicester, UK. The experimental animals were divided into two groups.
Group 1 (Noninduced; n=5) were maintained on a normal, non-I3C rat diet (diet TD 99414,
Harlan-Teklad, Madison, WI) for 10 days. Group 2 (Hypertensive; n=5) were littermates fed
a normal rat diet containing 0.3% I3C (wt/wt; diet TD 05381, Harlan-Teklad) for 10 days to
induce ANG II-dependent malignant hypertension. The rats were allowed free access to food
and tap water until the day of the experiment. Body weight was measured throughout the
course of the study.
At the conclusion of the treatment period, all animals were surgically prepared for
assessment of renal hemodynamics and continuous measurement of arterial blood pressure
as described previously.6 Briefly, the rats were anesthetized with pentobarbital sodium (50
mg/kg, ip) and placed on a surgical table thermostatically controlled to maintain body
temperature at 37°C. A tracheostomy was performed, and the animals were allowed to
breathe humidified air enriched with oxygen. The left jugular vein was cannulated to allow
infusion of solutions and additional anesthetic. The rats were infused at a constant rate of 1.2
ml/h with isotonic saline containing 6% albumin (bovine; Sigma Chemical, St. Louis, MO)
during surgery and thereafter with isotonic saline containing 1% albumin, 7.5%
polyfructosan (Inutest; Laevosan Geselschaft, Linz, Austria), and 1.5% p-aminohippurate
sodium (PAH; Merck Sharp & Dohme, West Point, PA). A catheter was inserted into the
left femoral artery to allow monitoring of arterial blood pressure and to facilitate collection
of blood samples. Blood pressure was monitored with a Statham pressure transducer (model
P23DC) and recorded using a computerized data-acquisition system (MP100 System;
BIOPAC Systems, Santa Barbara, CA) with the AcqKnowledge Software Package (version
3.7.3, BIOPAC). The left kidney was exposed via a flank incision, freed from surrounding
tissue, and placed in a Lucite cup. The left ureter was cannulated to allow timed urine
collections to be obtained.
After a 45 minute recovery period, urine was collected during two 30-minute control
periods, followed by a control blood sample (~250 µL). Aliskiren (Novartis Pharma AG,
Basel, Switzerland; 10 mg/kg) was administered by iv bolus injection into the left jugular
vein. The dose of aliskiren used in the present study was chosen on the basis of the previous
observation that chronic administration of this dose of aliskiren elicited a pronounced and
prolonged decrease in blood pressure in hypertensive TGR(mRen2)27 transgenic rats, which
constitutively express high levels of the mouse Ren2 renin gene.13 After a 15-minute
equilibration period, urine was collected during two 30-minute experimental periods,
followed by collection of an additional blood sample (~250 µL). At the conclusion of the
protocol, the left kidney was excised, blotted dry, and weighed.
Urine volume was determined gravimetrically. Sodium concentration in urine and plasma
were measured using flame photometry. Inulin and PAH concentrations in both urine and
plasma were measured by standard spectrophotometry. Glomerular filtration rate (GFR) and
renal plasma flow (RPF) were estimated from the clearance of inulin and PAH, respectively.
Renal blood flow (RBF) was calculated as RPF/(1-Hct). Renal vascular resistance (RVR)
was determined from the quotient of mean arterial pressure (MAP) and calculated renal
blood flow.
Statistical analyses were performed within groups using one-way repeated measures
ANOVA followed by Student-Newman-Keuls test where appropriate and between groups
using one-way ANOVA followed by Student-Newman-Keuls test where appropriate. All
statistical analyses were performed using SigmaPlot for Windows (version 11; Systat
Software Inc., San Jose, CA). Statistical significance was defined as P<0.05. All data are
expressed as means ± SE.
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Results
Chronic dietary administration of 0.3% I3C to Cyp1a1-Ren2 rats (n=5) for 10 days resulted
in the development of severe hypertension (194±7 vs. 141±2 mmHg, P<0.001; Fig. 1). The
development of hypertension was associated with a marked decrease in body weight
(261±14 to 200±17 g, P<0.001), which was not seen in the animals maintained on a non-I3C
containing diet. The hypertensive rats also demonstrated severe lethargy, piloerection and
assumption of hunched posture, which are manifestations of malignant hypertension in the
rat.1,5,6 Thus, in the present study, chronic dietary administration of 0.3% I3C induced
malignant hypertension in the Cyp1a1-Ren2 rats, as previously observed.1,5,6 As shown in
Fig. 1, aliskiren administration elicited a pronounced decrease in MAP in the hypertensive
rats (194±7 to 136±2 mmHg, P<0.001), but not in the noninduced rats (141±2 to 136±4,
NS).
As shown in Figs. 2 and 3, basal values for GFR and RPF in the hypertensive rats were
lower than the corresponding values in the noninduced normotensive rats (1.01±0.07 vs.
1.34±0.06 ml/min.g, P=0.01, and 2.47±0.23 vs. 4.17±0.35 ml/min.g, P<0.001, respectively).
Aliskiren administration increased GFR (1.01±0.07 to 1.18±0.08, P<0.05) and RPF
(2.47±0.23 to 4.31±0.20 ml/min.g, P<0.001) in the hypertensive rats but not in the
noninduced rats. However, GFR in the aliskiren-treated hypertensive rats remained
significantly lower than that observed in the aliskiren-treated normotensive control rats
(1.18±0.08 vs. 1.50±0.06 ml/min.g, P<0.01). Although there was a tendency for dietary
administration of 0.3% I3C to raise filtration fraction, the increase did not achieve statistical
significance (42±5 vs. 33±2%, NS). Upon systemic administration of aliskiren, filtration
fraction significantly decreased in hypertensive rats (42±5 to 28±1%, P<0.05) but remained
unaltered in the noninduced control rats (33±2 to 35±2, NS). As shown in Fig. 4, the basal
value for RVR in the hypertensive rats was markedly greater than that in the noninduced rats
(41.0±3.2 vs. 17.7±1.3 mmHg/ml/min.g, P<0.001). Aliskiren administration normalized
RVR in the hypertensive rats (41.0±3.2 to 17.6±1.6 mmHg/ml/min.g, P<0.001) but did not
alter RVR in the normotensive rats.
As shown in Fig. 5, control values for urine flow in the hypertensive rats were significantly
greater than those observed in the noninduced rats (12.08±0.89 vs. 6.73±0.44 µL/min,
P<0.001). However, the basal value for urinary sodium excretion in the hypertensive rats
was not different from the corresponding value in the noninduced normotensive rats
(300±123 vs. 141±42 nEq/min) (Fig. 6). Urine flow remained unaltered following aliskiren
administration in both groups (Fig. 5). In contrast, aliskiren increased urinary sodium
excretion in the normotensive rats (141±42 to 515±107 nEq/min, P<0.05), but not in the
hypertensive rats (300±123 to 158±52).
Discussion
The present study was performed to evaluate the effects of acute direct renin inhibition with
aliskiren on blood pressure and renal hemodynamics and excretory function in Cyp1a1-Ren2
transgenic rats with inducible ANG II-dependent malignant hypertension. In the present
study, induction of the Ren2 renin gene by dietary administration of 0.3% I3C for 10 days
resulted in the development of hypertension. The hypertension was associated with a
pronounced decrease in body weight, and the rats also exhibited extreme lethargy,
assumption of a hunched posture, and piloerection, which are clinical manifestations of
malignant hypertension in the rat.1,5,6 Acute administration of the direct renin inhibitor,
aliskiren, resulted in a rapid normalization of mean arterial blood pressure in the five rats
studied. This finding indicates that renin generated as a consequence of expression of the
Howard et al. Page 4
Am J Med Sci. Author manuscript; available in PMC 2012 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ren2 renin gene is responsible for the maintenance of malignant hypertension in Cyp1a1-
Ren2 transgenic rats.
Cyp1a1-Ren2 transgenic rats exhibited significantly decreased values for GFR and RPF and
significantly elevated RVR. These findings are consistent with our previous observations
that GFR and RPF are maintained within or slightly below the normal range and that RVR is
significantly elevated in Cyp1a1-Ren2 transgenic rats with malignant hypertension.6 The
present study does not allow determination of the relative contribution of the autoregulatory
response to the increased arterial pressure or of the direct pre- and post-glomerular
vasoconstrictor effects of ANG II to the reduced GFR and RPF and elevated RVR in
Cyp1a1-Ren2 transgenic rats with malignant hypertension. Whatever the mechanism, the
present data confirm our previous findings that the ability of the pre-glomerular vasculature
to prevent the transmission of the systemic hypertension to the glomerular capillaries
appears to be intact at the stage of the pathogenesis of malignant hypertension.5
In the present study, aliskiren administration increased GFR and RPF and decreased RVR
and filtration fraction in the hypertensive rats but not in the noninduced rats. The
observation that acute aliskiren administration significantly reduced filtration fraction in the
hypertensive rats is consistent with our previous observation that chronic administration of
the AT1 receptor antagonist, candesartan, prevented the increase in filtration fraction in rats
induced with 0.3% I3C for 11–12 days.6 Collectively, these findings indicate that ANG II
generated as a consequence of Ren2 renin gene expression contributes to an elevated
filtration fraction in Cyp1a1-Ren2 rats with malignant hypertension.
Although aliskiren treatment increased GFR in the hypertensive rats, GFR in the aliskiren-
treated hypertensive rats remained significantly lower than the GFR in the aliskiren-treated
noninduced normotensive rats (Fig. 2). It is possible that the sustained reduction of GFR in
the aliskiren-treated hypertensive rats reflects the glomerular damage that occurred during
the development of malignant hypertension. In this regard, we have previously demonstrated
that the renal pathological changes that occur during the development of malignant
hypertension in Cyp1a1-Ren2 rats are characterized by myointimal hyperplasia and tubular
dilation, inflammation and cellular proliferation in the cortical vessels and
tubulointerstitium, and pronounced glomerulosclerosis.5 One would predict that acute
aliskiren administration would be unlikely to reverse such renal vascular and glomerular
injury and that this likely contributed to the inability of acute aliskiren treatment to restore
GFR to levels observed in the aliskiren-treated noninduced control rats. Nevertheless, it is
likely that the increases in GFR and RPF, and the reductions in total RVR and filtration
fraction after acute aliskiren administration occurred as a consequence of vasodilation of
both pre- and post-glomerular vascular resistance elements. Whatever the relative
contribution of pre- and post-glomerular vasodilation to the elevated GFR and RPF, the
observation that GFR and RPF increased significantly following aliskiren administration
indicates that the glomerular vascular resistance vessels can vasodilate in response to direct
renin inhibition and to subsequent reduction of the renal vasoconstrictor actions of ANG II.
Despite the markedly elevated arterial blood pressure, the control values for urinary sodium
excretion in the hypertensive rats were not significantly different from those observed in the
noninduced normotensive rats. However, the basal values for urine flow in the hypertensive
rats were higher than those in the normotensive rats, presumably reflecting the pressure
diuretic effects of the elevated blood pressure. In contrast, the finding that basal values of
sodium excretion in the hypertensive rats were not different from those in normotensive rats
indicates that the kidneys of Cyp1a1-Ren2 rats with malignant hypertension exhibit an
impaired natriuretic response to elevated arterial blood pressure and can maintain normal
rates of sodium excretion only at hypertensive arterial pressures. Administration of aliskiren
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increased urinary sodium excretion in the noninduced normotensive rats but not in the
hypertensive rats. In contrast, we previously observed that chronic administration of the AT1
receptor antagonist, candesartan, increased sodium excretion in Cyp1a1-Ren2 rats induced
with 0.3% I3C.6 The reasons for these apparent disparate findings remain unclear but are
likely related to the fact that in the present study the aliskiren-treated hypertensive rats
exhibited a rapid and pronounced (~60 mmHg) decrease in arterial blood pressure which
would have masked any effect of acute direct renin inhibition to increase sodium excretion.
In contrast, chronic AT1 receptor blockade with candesartan prevented the development of
malignant hypertension rather than rapidly normalizing a markedly elevated arterial blood
pressure6 which would likely allow manifestation of the natriuretic effects of chronic AT1
receptor blockade in this model. In the present study, the aliskiren-induced pronounced
decrease in arterial blood pressure likely acted to offset any renal natriuretic effects of direct
renin inhibition by aliskiren.
It has been demonstrated that in the kidney, aliskiren localizes extensively in the glomeruli,
the JG cells of the afferent arteriole and the larger caliber intrarenal arteries.8 Thus, it is
possible that in addition to inhibiting circulating renin, acute aliskiren administration also
inhibited renal renin and that this contributed in part to the renal functional responses to
acute aliskiren administration. However, the present study does not allow discrimination
between the relative contributions of inhibition of circulating versus kidney tissue renin to
the observed renal functional responses to acute aliskiren administration. Further studies are
required to address this issue.
It has been reported that aliskiren is able to bind both circulating and receptor bound
prorenin to decrease ANG I and II generation.8 Thus it is possible that prorenin contributed
to the hypertensive phenotype in Cyp1a1-Ren2 transgenic rats and that the blood pressure
and renal functional responses to acute aliskiren administration observed in the present study
occurred, in part, as a consequence of inhibition of both circulating and receptor bound
prorenin. However, the present data do not allow determination of the relative contribution
of prorenin inhibition to the blood pressure and renal functional responses to acute aliskiren
administration. Additional studies are required to address this issue.
In summary, the present data demonstrate that acute direct renin inhibition with aliskiren
normalizes mean arterial blood pressure, increases GFR and RPF, and decreases RVR and
filtration fraction in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent
malignant hypertension. The normalization of arterial blood pressure, the increases in GFR
and RPF, and the decreases in RVR and filtration fraction indicate that renin generated as a
consequence of expression of the Ren2 Renin gene is responsible for the maintenance of
malignant hypertension and reduced renal hemodynamic function in Cyp1a1-Ren2
transgenic rats.
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FIG. 1.
Mean arterial blood pressure in anesthetized noninduced and hypertensive Cyp1a1-Ren2 rats
during control conditions and after acute bolus injection of aliskiren (10 mg/kg, iv);
*P<0.001 vs. Noninduced; #P<0.001 vs. Corresponding control.
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FIG. 2.
Glomerular filtration rate in anesthetized noninduced and hypertensive Cyp1a1-Ren2 rats
during control conditions and after acute bolus injection of aliskiren (10 mg/kg, iv). *P<0.05
vs. Noninduced; #P<0.05 vs. Corresponding control.
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FIG. 3.
Renal plasma flow in anesthetized noninduced and hypertensive Cyp1a1-Ren2 rats during
control conditions and after acute bolus injection of aliskiren (10 mg/kg, iv); *P<0.001 vs.
Noninduced; #P<0.001 vs. Corresponding control.
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FIG. 4.
Renal vascular resistance in anesthetized noninduced and hypertensive Cyp1a1-Ren2 rats
during control conditions and after acute bolus injection of aliskiren (10 mg/kg, iv);
*P<0.001 vs. Noninduced; #P<0.001 vs. Corresponding control.
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FIG. 5.
Urine flow in anesthetized noninduced and hypertensive Cyp1a1-Ren2 rats during control
conditions and after acute bolus injection of aliskiren (10 mg/kg, iv); *P<0.01 vs.
Noninduced.
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FIG. 6.
Urinary sodium excretion in anesthetized noninduced and hypertensive Cyp1a1-Ren2 rats
during control conditions and after acute bolus injection of aliskiren (10 mg/kg, iv); #P<0.05
vs. Corresponding control.
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